BioVersys Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
40
- Stock Symbol
-
BIOV
- Share Price
-
$27.99
- (As of Friday Closing)
BioVersys General Information
Description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
Contact Information
Website
www.bioversys.comCorporate Office
- C/o Technologiepark
- Hochbergerstrasse 60c
- 4057 Basel
- Switzerland
Corporate Office
- C/o Technologiepark
- Hochbergerstrasse 60c
- 4057 Basel
- Switzerland
BioVersys Stock Performance
As of 13-Nov-2026, BioVersys’s stock price is $27.99. Its current market cap is $164M with 5.85M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $27.99 | $28.71 | $26.34 - $38.48 | $164M | 5.85M | 2.29K | -$5.67 |
BioVersys Financials Summary
As of 30-Jun-2026, BioVersys has a trailing 12-month revenue of $2.02M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 116,598 | 86,966 | ||
| Revenue | 2,016 | 963 | 0 | |
| EBITDA | (31,319) | (24,648) | (20,326) | |
| Net Income | (33,278) | (26,266) | (21,259) | (20,358) |
| Total Assets | 95,195 | 114,451 | 38,688 | |
| Total Debt | 27,450 | 27,438 | 18,776 |
BioVersys Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
BioVersys Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
BioVersys Comparisons
Industry
Financing
Details
BioVersys Competitors (20)
One of BioVersys’s 20 competitors is Armata Pharmaceuticals, a Formerly VC-backed company based in Los Angeles, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Armata Pharmaceuticals | Formerly VC-backed | Los Angeles, CA | ||||
| Lisata Therapeutics | Corporation | Basking Ridge, NJ | ||||
| Nabriva Therapeutics | Formerly VC-backed | Dublin, Ireland | ||||
| Capricor Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Macrogenics | Formerly VC-backed | Rockville, MD |
BioVersys Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
BioVersys Patents
BioVersys Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026210002-A1 | Rifabutin ester analogs for the treatment of disease | Pending | 03-Apr-2025 | ||
| EP-4696694-A1 | Antibiotic rifabutin analogs | Pending | 14-Aug-2024 | ||
| EP-4696695-A1 | Antibiotic rifabutin analogs | Pending | 14-Aug-2024 | ||
| WO-2026037897-A1 | Antibiotic rifabutin analogs | Pending | 14-Aug-2024 | ||
| WO-2026037898-A1 | Antibiotic rifabutin analogs | Pending | 14-Aug-2024 | C07D498/22 |
BioVersys Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
BioVersys Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
BioVersys ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
BioVersys Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Ruibaiwei Pharmaceutical | Guangzhou, China | 2024 |
BioVersys FAQs
-
When was BioVersys founded?
BioVersys was founded in 2008.
-
Where is BioVersys headquartered?
BioVersys is headquartered in Basel, Switzerland.
-
What is the size of BioVersys?
BioVersys has 40 total employees.
-
What industry is BioVersys in?
BioVersys’s primary industry is Drug Discovery.
-
Is BioVersys a private or public company?
BioVersys is a Public company.
-
What is BioVersys’s stock symbol?
The ticker symbol for BioVersys is BIOV.
-
What is the current stock price of BioVersys?
As of 13-Nov-2026 the stock price of BioVersys is $27.99.
-
What is the current market cap of BioVersys?
The current market capitalization of BioVersys is $164M.
-
What is BioVersys’s current revenue?
The trailing twelve month revenue for BioVersys is $2.02M.
-
Who are BioVersys’s competitors?
Armata Pharmaceuticals, Lisata Therapeutics, Nabriva Therapeutics, Capricor Therapeutics, and Macrogenics are some of the 20 competitors of BioVersys.
-
What is BioVersys’s annual earnings per share (EPS)?
BioVersys’s EPS for 12 months was -$5.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
